NASDAQ$TERN
Terns Pharmaceuticals Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Terns reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Terns Pharmaceuticals reported a net loss of $13.3 million for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $195.6 million as of March 31, 2021, which is expected to fund operations into 2024.
- Phase 2a LIFT study of TERN-101 top-line data expected in June 2021.
- First clinical trial of TERN-501 initiated in March, with top-line data expected in the second half of 2021.
- Dosing in Phase 1b clinical trial of TERN-201 expected to initiate in 1H21.
- Completed an oversubscribed $147 million initial public offering in February 2021.
Headline financials
Revenue & EPS history
Terns · Revenue · Quarterly
$0
Forward guidance
Terns Pharmaceuticals is focused on advancing its NASH clinical programs and expects to nominate a final candidate for GLP1-R in 2H21. The company anticipates that its cash and equivalents will support operations into 2024.
Tailwinds
- Top-line data from the Phase 2a LIFT study of FXR agonist TERN-101 in NASH is expected in June 2021.
- Top-line data from the first clinical trial of TERN-501 is expected in the second half of 2021.
- Dosing in 12-week Phase 1b clinical trial in NASH patients of TERN-201 is expected to initiate in 1H21 with expected top-line data in 1H22.
- A final candidate for GLP1-R is expected to be nominated in 2H21 for further development.
- Cash and equivalents are expected to support operations into 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
-0.3%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+16.4%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+19.8%
Q4 2022
Best reaction
-23.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.3% | -0.0% | — | |
| Q3 2025 | +7.6% | +18.0% | +146.3% | |
| Q2 2025 | -6.8% | +3.6% | +18.7% | |
| Q1 2025 | -0.7% | -4.1% | +22.3% | |
| Q4 2024 | -2.7% | -1.3% | -23.6% | |
| Q3 2024 | -9.1% | -17.3% | -11.7% | |
| Q2 2024 | -4.6% | -11.8% | -1.7% | |
| Q1 2024 | +7.7% | +6.1% | +32.9% | |
| Q4 2023 | +1.7% | -15.0% | -27.4% | |
| Q3 2023 | +14.2% | +10.1% | +92.3% | |
| Q2 2023 | -9.5% | +0.8% | -21.5% | |
| Q1 2023 | -15.2% | -20.3% | -7.0% | |
| Q4 2022 | +19.8% | +32.7% | +42.3% | |
| Q3 2022 | -23.0% | -26.7% | -12.2% | |
| Q2 2022 | -5.5% | +39.2% | +75.1% | |
| Q1 2022 | +4.0% | -0.7% | +26.5% | |
| Q4 2021 | +4.1% | +3.5% | -5.4% | |
| Q3 2021 | -1.2% | -5.9% | -30.9% | |
| Q2 2021 | +4.3% | +3.5% | -0.9% | |
| Q1 2021 | +3.6% | +5.6% | +13.5% | |
| Q4 2020 | +5.8% | -0.9% | +1.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro